PR Newswire
13 Jun 2022, 18:50 GMT+10
MILAN, June 13, 2022 /PRNewswire/ -- Dompe farmaceutici S.p.A ("Dompe") today announced results from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results. Results from the Phase 2 trial are published in Infectious Diseases and Therapy and were presented at the scientific sessions of the ATS 2022 International Conference in San Francisco, California.
Acute lung injury and acute respiratory distress syndrome (ARDS) are common complications in patients with COVID-19.1 As part of its commitment to invest in research for unmet medical needs, Dompe conducted an open-label, multi-center study to evaluate the inhibition of IL-8 which is known to be associated with cytokine release syndrome connected to Covid-19 disease.
"Reparixin is a new investigational molecule that seems to have a novel application in patients with acute respiratory inflammation induced by COVID-19. It was well tolerated in clinical studies," said Giovanni Landoni, MD, Director of CARE (Center for Intensive Care and Anesthesiology) at Hospital San Raffaele in Milan, Italy. "The outcomes as compared to the standard of care may now be reduced by the widespread use of COVID-19 vaccines, but the obtained results indicated continued investigation would be valuable in patients with acute respiratory inflammation."
Fifty-five patients were randomized 2:1 to receive 1200 mg of oral Reparixin, an inhibitor of IL-8, three times daily or the standard of care for up to 21 days. The rate of clinical events was statistically significantly lower in the Reparixin group compared to those assigned to the group receiving standard of care (27% vs. 42.1%, p=0.02). Treatment with Reparixin was well-tolerated in terms of treatment-emergent adverse events, laboratory test and vital sign parameters2.
"Dompe, along with the rest of the biopharmaceutical world, has worked with urgency to fight COVID-19 and its complications," said Flavio Mantelli, Chief Medical Officer at Dompe. "While vaccines have helped to mitigate severity of disease, in-hospital treatment options for those who are most seriously impacted remain limited. We are dedicated to this patient population, we are looking forward to continuing our clinical development program to evaluate the potential to reduce COVID-19 respiratory complications."
About the Study3
The study was an open-label, multicenter, randomized, phase 2 clinical trial designed to assess the efficacy and safety of oral Reparixin in adult patients hospitalized with severe COVID-19 pneumonia from May 5, 2020, until November 27, 2020 and now released for the first time. The study enrolled 55 adults (aged 18-90 years old) hospitalized with severe COVID-19 pneumonia, assigned randomly 2:1 to receive 1200mg Reparixin orally three times daily or standard of care (SOC) for up to 21 days. At least one treatment emergent adverse event occurred in 3 patients in the Reparixin group, and 5 patients in SOC. Reparixin overall appeared to be well tolerated.
All patients received the standard care based on their clinical need, including COVID-19 medications, as per local standard therapy at the trial site hospital and in line with international guidelines.
Please refer to NCT04794803 for additional clinical trial details.
About Dompe
Dompe is a privately-held biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of R&D and medical innovation. Today, Dompe, with Headquarters in Milan, employs more than 800 employees worldwide, with a commercial operations hub in the San Francisco Bay Area, U.S.
Forward Looking Statements
This press release refers to certain information that may not coincide with expected future results. Dompe firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompe cannot guarantee that the expected results will be consistent with the information provided above.
References
1. Tzotzos SJ, et al. Crit Care. 2020 Aug 21;24(1).
2. A phase 2 multicenter, randomized, controlled study to evaluate the efficacy and safety of Reparixin in hospitalized adult patients with COVID-19 pneumonia, ATS 2022 International Conference in San Francisco, California.
3. https://www.springer.com/journal/40121
SOURCE Dompe Farmaceutici S.p.A
Get a daily dose of Malaysia Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Malaysia Sun.
More InformationHANOI, Vietnam: As Vietnam seeks to strengthen trade ties and avoid potential U.S. tariffs, companies from both countries signed agreements...
NEW DELHI, India: Jaguar Land Rover (JLR) has decided against manufacturing electric vehicles at Tata Motors' upcoming $1 billion factory...
(250320) -- RIYADH, March 20, 2025 (Xinhua) -- Head coach of China Branko Ivankovi (C) speaks during the press conference before the...
New Delhi [India], March 20 (ANI): Philippines Foreign Secretary Enrique Manalo described the deal between India and the Philippines...
Photo taken on March 19, 2025 shows spring scenery in Islamabad, capital of Pakistan. (XinhuaAhmad Kamal)ISLAMABAD, March 20 (Xinhua)...
Washington DC [US], March 20 (ANI): US Department of State Spokesperson Tammy Bruce on Wednesday condemned the violence against minorities...
NEW YORK, New York - U.S. stocks rose Wednesday despite the U.S. Federal Reserve signalling a potential slowdown in the U.S. economy,...
WASHINGTON, D.C.: President Donald Trump has reversed a Biden-era executive order requiring businesses with federal contracts to pay...
FRANKFURT, Germany: UBS CEO Sergio Ermotti will receive a pay package of just over 15 million Swiss francs (US$17 million) for 2024,...
PARIS, France: French Prime Minister Francois Bayrou acknowledged over the weekend that the European Union may have miscalculated by...
NEW YORK, New York - Sellers took charge again on Wall Street Tuesday as the brief rebound that took place on Monday petered out. Stocks...
WASHINGTON, D.C.: The Trump administration has approved a plan to expand a coal mine in Montana and keep it running for 16 more years,...